



5-3-05

JFJ

CASE 4-32459A

<u>FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10</u>	
EV483469366US Express Mail Label Number	5-2-05 Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
DRESSMAN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/04007

FILED: 16 APRIL 2003

U.S. APPLICATION NO: 10/510,969

35 USC §371 DATE: 22 MARCH 2005

FOR: METHODS TO PREDICT PATIENT RESPONSIVENESS TO  
TYROSINE KINASE INHIBITORS**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



John T. Prince  
Attorney for Applicants  
Reg. No. 43,019

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(617) 871-3346

Date: May 2, 2005

## INFORMATION DISCLOSURE CITATION



(Use several sheets if necessary)

Sheet 1 of 2

ATTY. DOCKET NO.  
4-32459A  
APPLICATION NO.  
10/510,969  
APPLICANT  
DRESSMAN ET AL.  
FILING DATE  
OCTOBER 12, 2004

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
	AM						<input type="checkbox"/> <input type="checkbox"/>
	AN						<input type="checkbox"/> <input type="checkbox"/>
	AO						<input type="checkbox"/> <input type="checkbox"/>
	AP						<input type="checkbox"/> <input type="checkbox"/>
	AQ						<input type="checkbox"/> <input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Affymetrix Product Information: "Human Genome U95AV2", Online! No. XP002215481 (2002)		
AS	Malinowski, et al., "Pharmacogenetic Analysis of Cytogenetic Response in Chronic Myelogenous Leukemia Patients Treated with Imatinib (Glivec/Gleevec, ST1571)", Blood, Vol. 98, pp. 306a (2001)		
AT	McLean, et al., "Correlation of Cytogenetic Response with Gene Expression Profiles in Chronic Myelogenous Leukemia Patients Treated with Imatinib (Gleevec/Glivec)", Blood, Vol. 100, pp. 527 (2002)		

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
4-32459A  
APPLICATION NO.  
10/510,969  
APPLICANT  
DRESSMAN ET AL.  
FILING DATE  
OCTOBER 12, 2004

Group

EXAMINER INITIAL

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Ohmine, et al., "Analysis of Differential Gene Expression between ST1571-Sensitive and Resistant BCR/ABL-positive Cell Lines by a DNA Microarray", Blood, Vol. 98, pp. 306a (2001)
	DB	Onida, et al., "Acquired In-vitro Resistance to ST1571 (Imatinib Mesylate) in BCR-ABL Positive Cell Lines: Investigation of Gene Expression by Molecular Pathway Microarrays", Blood, Vol. 98, pp. 567a-568a (2001)
	DC	Relling, et al., "Pharmacogenetics and Cancer Therapy", Nature Rev. Cancer, Vol. 1, pp. 99-108 (2001)
	DD	Von Bubnoff, et al., "Gene Expression Profiles of Leukemic Cells Isolated from Patients with Chronic Myeloid Leukemia (CML) and Philadelphia-positive Acute Lymphoblastic Leukemia (PH+ ALL) Receiving the Abl-kinase Inhibitor ST1571", Blood, Vol. 98, 567a (2001)
	DE	Yeoh, et al., "Classification, Subtype Discovery, and Prediction of Outcome in Pediatric Acute Lymphoblastic Leukemia by Gene Expression Profiling", Cancer Cell, Vol. 1, pp. 133-143 (2002)
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.